Another rare disease drug will be withdrawn from the Chinese market, with some patients claiming to have spent 1 million RMB on taking Ositratin for 4 years.

Recently, Recordati, an Italian pharmaceutical company, announced the official cancellation of registration for its wholly-owned Chinese subsidiary Ricondi, which means it will completely withdraw from the Chinese market. With Ricondi's exit, several rare disease drugs from the company will also cease supply to China, including the only oral drug for treating Cushings syndrome in China, Osilodrostat. Osilodrostat was approved domestically in China in September 2024 and officially commercialized in China in April 2025, but has only been on the market for less than a year. However, since 2021, the drug has been used as a pilot project in Bo'ao Lecheng. For patients with Cushings syndrome, the exit of Ricondi means the discontinuation of a "life-saving drug". According to media reports, a patient with Cushings syndrome who has been taking Osilodrostat for four years said that in these years, he has spent "1 million RMB" on the medication.